Emily E. Coates - Concepedia

Author

Emily E. Coates

National Institute of Allergy and Infectious Diseases ORCID

Also Known As

E.E. Coates, Emily Coates, Emily E Coates, Emily E. Coates, J E Ledgerwood, Kandiyil, Vidya Vijayan Karuvan

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

National Institute of Allergy and Infectious Diseases National Institutes of Health Frederick National Laboratory for Cancer Research Leidos (United States)Walter Reed Army Institute of Research

About

Emily E. Coates is an author at National Institute of Allergy and Infectious Diseases specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.6K
2	Engineering	3	3	408
3	Cell Biology	3	3	408
4	Biomedical Engineering	2	2	296
5	Epidemiology	1	1	18

Emily E. Coates

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection Rebecca M. Lynch, Eli Boritz, Emily E. Coates, Science Translational Medicine Hiv-1 Cd4Human RetrovirusPassive ImmunizationImmunologyAntiviral Response	2015	454
Extracellular matrix formation and mineralization on a phosphate-free porous bioactive glass scaffold using primary human osteoblast (HOB) cells Julian R. Jones, Olga Tsigkou, Emily E. Coates, Biomaterials Tissue EngineeringEngineeringBone RepairBioceramicBiomedical Engineering	2006	281
Chimpanzee Adenovirus Vector Ebola Vaccine Julie E. Ledgerwood, Adam DeZure, Daphne A. Stanley, New England Journal of Medicine	2014	281
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults Martin R. Gaudinski, Emily E. Coates, Katherine V. Houser, PLoS Medicine	2018	249
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial Katherine V. Houser, Grace Chen, Cristina Carter, Nature Medicine VaccinologyVaccine SafetyVaccinationCross-protectionVaccine Development	2022	153
Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin Sarah F. Andrews, Michael Chambers, Chaim A. Schramm, Immunity VaccinationAdaptive Immune SystemImmunologyCd4 T Cell ResponsesInfluenza Hemagglutinin	2019	140
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
Preferential induction of cross-group influenza A hemagglutinin stem–specific memory B cells after H7N9 immunization in humans Sarah F. Andrews, Michael Joyce, Michael Chambers, Science Immunology Immunoglobulin Repertoire AnalysisAdaptive Immune SystemHumoral ResponseImmunologyImmunodominance	2017	114
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria Richard L Wu, Azza H. Idris, Nina M. Berkowitz, New England Journal of Medicine	2022	114
Neural differentiation of pluripotent cells in 3D alginate-based cultures Angela Bozza, Emily E. Coates, Tania Incitti, Biomaterials Tissue EngineeringNeural DifferentiationEngineeringBiofabricationCell Culture	2014	112

Page 1